Modern concepts about lysosomal acid lipase deficiency (review)

Lysosomal acid lipase deficiency is a rare heterogeneous autosomal recessive heterogeneous genetic disorder whose manifestations often result in severe morbidity and mortality. The development of the disease is associated with the accumulation of cholesterol esters and triglycerides in organs and tissues, which in turn leads to the development of atherosclerosis, hepatosplenomegaly, liver cirrhosis, malabsorption syndrome and other symptoms. The true prevalence of the disease is unknown, the estimated incidence in Russia is 1 : 100,000–150,000 of the child population. Depending on the residual activity of the enzyme, 2 variants of the clinical course of the disease are distinguished. The most severe and also rare variant is Wolman’s disease, identified and described in 1961 by Israeli neurologist Moshe Wolman. This disease progresses during the first year of a child’s life and in most cases, due to the difficulties of diagnosis, leads to the death of patients. A milder but more common variant of LAL-D, occurring in children over one year of age and adults, is cholesteryl ester storage disease, described in 1968. The nonspecificity of symptoms of LAL-D at an early stage leads to the fact that the diagnosis of this condition is prolonged or missed by clinicians. An increase in liver enzymes in combination with hepato- and splenomegaly, dyslipidemia should alert the doctor and lead to early diagnosis of LAL-D even at the outpatient stage of examination, thereby increasing the duration and quality of life of patients. Differential diagnosis is carried out with Gaucher disease, Niemann–Pick disease, familial hypercholesterolemia, non-alcoholic steatohepatitis and other storage diseases. The main method of treatment is enzyme replacement therapy with sebelipase-alpha. Studies have shown its effectiveness in increasing the life expectancy of patients. It is recommended to use a multidisciplinary approach in the management of patients with LAL-D at all stages, since the disease is characterized by damage to many organs and systems and requires complex therapy. The biochemical and pathophysiological processes occurring in the body with deficiency of lysosomal acid lipase are considered.

Authors

Institutions

Publication Details

Journal
Pediatrician (St Petersburg)
Published
2024-09-19
DOI
https://doi.org/10.17816/ped15263-70
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Modern concepts about lysosomal acid lipase deficiency (review)

Н. М. Щербак, В. А. Щербак, Nadezhda N. Kotova
Pediatrician (St Petersburg)
Lysosomal Storage Disorders Research
article

Modern concepts about lysosomal acid lipase deficiency (review)

Н. М. Щербак, В. А. Щербак, Nadezhda N. Kotova
article en

Abstract

Lysosomal acid lipase deficiency is a rare heterogeneous autosomal recessive heterogeneous genetic disorder whose manifestations often result in severe morbidity and mortality. The development of the disease is associated with the accumulation of cholesterol esters and triglycerides in organs and tissues, which in turn leads to the development of atherosclerosis, hepatosplenomegaly, liver cirrhosis, malabsorption syndrome and other symptoms. The true prevalence of the disease is unknown, the estimated incidence in Russia is 1 : 100,000–150,000 of the child population. Depending on the residual activity of the enzyme, 2 variants of the clinical course of the disease are distinguished. The most severe and also rare variant is Wolman’s disease, identified and described in 1961 by Israeli neurologist Moshe Wolman. This disease progresses during the first year of a child’s life and in most cases, due to the difficulties of diagnosis, leads to the death of patients. A milder but more common variant of LAL-D, occurring in children over one year of age and adults, is cholesteryl ester storage disease, described in 1968. The nonspecificity of symptoms of LAL-D at an early stage leads to the fact that the diagnosis of this condition is prolonged or missed by clinicians. An increase in liver enzymes in combination with hepato- and splenomegaly, dyslipidemia should alert the doctor and lead to early diagnosis of LAL-D even at the outpatient stage of examination, thereby increasing the duration and quality of life of patients. Differential diagnosis is carried out with Gaucher disease, Niemann–Pick disease, familial hypercholesterolemia, non-alcoholic steatohepatitis and other storage diseases. The main method of treatment is enzyme replacement therapy with sebelipase-alpha. Studies have shown its effectiveness in increasing the life expectancy of patients. It is recommended to use a multidisciplinary approach in the management of patients with LAL-D at all stages, since the disease is characterized by damage to many organs and systems and requires complex therapy. The biochemical and pathophysiological processes occurring in the body with deficiency of lysosomal acid lipase are considered.

Pediatrician (St Petersburg)Vol. 15(2)
Chita State Academy of Medicine (RU)
Openalex Percentile: Top 78%
Lysosomal Storage Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.